August 18, 2014 | According to a “Globes” report, Novartis AG will acquire Gamida Cell, a developer of stem cell therapies including one for the treatment of blood cancer. The deal, which was previously called off, is back on, but will not involve an exit of millions of dollars and instead will occur in stages of investment from Novartis. Later in the process, Gamida Cell shareholders are expected to sell their holdings for a large sum. However, the deal still remains subject to the completion of Gamida Cell’s product NiCord, a blood cancer treatment. Gamida Cell is headed by CEO Dr. Yael Margolin.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments